Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
NCT04007588 · Dana-Farber Cancer Institute · PHASE2 · withdrawn · last registry update 2020-02-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual” | – | Registry record, Dana-Farber Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-02-03Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Belzutifan (NCT04736706)
- 2020-11-03Phase 3 first posted: Mirati Therapeutics Inc., Adagrasib + Adagrasib (NCT04613596)
- 2020-09-01Phase 3 first posted: BioNTech SE, BNT113 + Pembrolizumab (NCT04534205)
- 2020-02-13Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT04267848)
- 2020-01-09Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Placebo for pembrolizumab (NCT04221945)
- 2019-12-24Phase 3 first posted: Merck Sharp & Dohme LLC, pembrolizumab + placebo (NCT04210115)
- 2019-12-11Phase 3 first posted: Eli Lilly and Company, Selpercatinib + Carboplatin (NCT04194944)
- 2019-04-16Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Paclitaxel (NCT03914612)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision